- Home
- CRBP vs MPA Comparison
CRBP vs MPA Comparison
Compare CRBP & MPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- MPA
- Stock Information
- Founded
- CRBP 2009
- MPA 1992
- Country
- CRBP United States
- MPA United States
- Employees
- CRBP N/A
- MPA N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- MPA Finance Companies
- Sector
- CRBP Health Care
- MPA Finance
- Exchange
- CRBP Nasdaq
- MPA Nasdaq
- Market Cap
- CRBP 143.7M
- MPA 159.3M
- IPO Year
- CRBP N/A
- MPA N/A
- Fundamental
- Price
- CRBP $11.93
- MPA $11.97
- Analyst Decision
- CRBP Strong Buy
- MPA
- Analyst Count
- CRBP 8
- MPA 0
- Target Price
- CRBP $62.00
- MPA N/A
- AVG Volume (30 Days)
- CRBP 256.8K
- MPA 25.2K
- Earning Date
- CRBP 03-11-2025
- MPA 01-01-0001
- Dividend Yield
- CRBP N/A
- MPA 3.83%
- EPS Growth
- CRBP N/A
- MPA N/A
- EPS
- CRBP N/A
- MPA N/A
- Revenue
- CRBP N/A
- MPA N/A
- Revenue This Year
- CRBP N/A
- MPA N/A
- Revenue Next Year
- CRBP N/A
- MPA N/A
- P/E Ratio
- CRBP N/A
- MPA N/A
- Revenue Growth
- CRBP N/A
- MPA N/A
- 52 Week Low
- CRBP $7.30
- MPA $9.87
- 52 Week High
- CRBP $61.90
- MPA $12.21
- Technical
- Relative Strength Index (RSI)
- CRBP 39.08
- MPA 54.66
- Support Level
- CRBP $11.02
- MPA $11.71
- Resistance Level
- CRBP $13.28
- MPA $11.99
- Average True Range (ATR)
- CRBP 0.74
- MPA 0.15
- MACD
- CRBP 0.16
- MPA 0.05
- Stochastic Oscillator
- CRBP 40.27
- MPA 90.00
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About MPA Blackrock MuniYield Pennsylvania Quality Fund
Blackrock Muniyield Pennsylvania Quality Fund is a closed-end fund with investment objective is to provide shareholders with current income exempt from U.S. federal and Pennsylvania income taxes.